Summary:
- AstraZeneca's new drug application for baxdrostat, a treatment for hard-to-control high blood pressure, has been accepted for priority review by the U.S. Food and Drug Administration (FDA).
- Baxdrostat is a novel medication that works by blocking an enzyme called aldosterone synthase, which plays a key role in regulating blood pressure.
- If approved, baxdrostat could provide a new treatment option for patients with difficult-to-manage high blood pressure, which is a major risk factor for heart disease and other serious health problems.